Edition:
United Kingdom

Alligator Bioscience AB (ATORX.ST)

ATORX.ST on Stockholm Stock Exchange

25.45SEK
18 Apr 2019
Change (% chg)

-0.05kr (-0.20%)
Prev Close
25.50kr
Open
25.50kr
Day's High
26.00kr
Day's Low
25.05kr
Volume
30,167
Avg. Vol
81,358
52-wk High
39.00kr
52-wk Low
20.30kr

Latest Key Developments (Source: Significant Developments)

Alligator Bioscience AB Oct-Dec Net Sales, SEK 51.3 Million
Friday, 16 Feb 2018 

Feb 16 (Reuters) - ALLIGATOR BIOSCIENCE AB ::OCT-DEC NET SALES, SEK 51.3 MILLION (6.4).OCT-DEC OPERATING RESULT, SEK 10.7 MILLION (-22.1).  Full Article

Alligator Bioscience appoints Charlotte A Russell as Chief Medical Officer​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - ALLIGATOR BIOSCIENCE AB ::ALLIGATOR BIOSCIENCE AB - ‍APPOINTMENT OF CHARLOTTE A RUSSELL AS CHIEF MEDICAL OFFICER​.ALLIGATOR BIOSCIENCE AB - ‍RUSSELL WILL JOIN ALLIGATOR FROM HER ROLE AS SENIOR MEDICAL DIRECTOR AT GENMAB A/S​.  Full Article

Alligator Bioscience ‍Q3 operating loss widens to SEK 24.5 mln​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - ALLIGATOR BIOSCIENCE AB :Q3 NET SALES, SEK 1.8 MILLION (4.7).‍Q3 OPERATING LOSS, SEK 24.5 MILLION (LOSS: 9.1)​.  Full Article

Alligator Bioscience Q2 operating loss lowers to SEK 29.5 ‍​mln
Wednesday, 23 Aug 2017 

Aug 23 (Reuters) - ALLIGATOR BIOSCIENCE AB ::Q2 NET SALES SEK 1.3 MILLION VERSUS SEK 3.8 MILLION YEAR AGO.Q2 OPERATING LOSS SEK 29.5 ‍​MILLION VERSUS LOSS SEK 47.7 MILLION YEAR AGO.  Full Article

Alligator Bioscience expands collaboration with Stanford University
Monday, 7 Aug 2017 

Aug 7 (Reuters) - ALLIGATOR BIOSCIENCE AB ::EXPANDS IMMUNO-ONCOLOGY COLLABORATION WITH STANFORD UNIVERSITY.  Full Article

Aptevo Therapeutics and Alligator Bioscience to co-develop novel bispecific antibody
Friday, 21 Jul 2017 

July 21 (Reuters) - ALLIGATOR BIOSCIENCE AB :APTEVO THERAPEUTICS AND ALLIGATOR BIOSCIENCE ANNOUNCE PLANS TO CO-DEVELOP NOVEL BISPECIFIC ANTIBODY FOR TUMOR-DIRECTED IMMUNOTHERAPY.‍PARTIES WILL JOINTLY OWN AND SHARE EQUALLY IN DEVELOPMENT COSTS ASSOCIATED WITH ADVANCING THIS CANDIDATE THROUGH TO END OF PHASE 2 CLINICAL DEVELOPMENT​.  Full Article

Alligator Bioscience advances ATOR-1017 into pre-clinical development​
Monday, 12 Jun 2017 

June 12 (Reuters) - ALLIGATOR BIOSCIENCE AB ::ALLIGATOR BIOSCIENCE ‍HAS ADVANCED ANOTHER WHOLLY-OWNED CHECKPOINT MODULATOR PROGRAM, ATOR-1017, INTO PRE-CLINICAL DEVELOPMENT​.  Full Article

Alligator Bioscience Q1 operating result swings to loss SEK 19.1 million
Tuesday, 2 May 2017 

May 2 (Reuters) - ALLIGATOR BIOSCIENCE AB :Q1 NET SALES SEK 2.5 MILLION VERSUS SEK 43.4 MILLION YEAR AGO.Q1 OPERATING LOSS SEK 19.1 MILLION VERSUS PROFIT SEK 24.1 MILLION YEAR AGO.  Full Article